Your browser doesn't support javascript.
loading
Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis.
Gisondi, P; Virga, C; Piaserico, S; Meneguzzo, A; Odorici, G; Conti, A; Girolomoni, G.
Afiliação
  • Gisondi P; Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
  • Virga C; Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
  • Piaserico S; Department of Medicine, Section of Dermatology and Venereology, University of Padua, Padua, Italy.
  • Meneguzzo A; Department of Medicine, Section of Dermatology and Venereology, University of Padua, Padua, Italy.
  • Odorici G; Department of Head and Neck Surgery, Section of Dermatology, Azienda Ospedaliero Universitaria Policlinico di Modena, Modena, Italy.
  • Conti A; Department of Head and Neck Surgery, Section of Dermatology, Azienda Ospedaliero Universitaria Policlinico di Modena, Modena, Italy.
  • Girolomoni G; Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
Br J Dermatol ; 183(2): 397-398, 2020 08.
Article em En | MEDLINE | ID: mdl-32133618
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Medicamentos Biossimilares Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Medicamentos Biossimilares Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article